The bio-molecular profile for bladder cancer patients is described as having alterations that affect the cellular cycle cyclin-dependent kinase Inhibitor 2A(CDKN2A)/CDK4/CCND1, PI3K/AKT/mTOR), but also survival and growth Receptor tyrosine kinases/RAS (RTK/RAS) pathways, with FGFR3 mutation incidence higher in NMIBC [9]. The gene discussed is MTOR; the disease is urinary bladder cancer.